Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03602079 |
|
Recruitment Status :
Active, not recruiting
First Posted : July 26, 2018
Last Update Posted : July 12, 2022
|
Sponsor:
Klus Pharma Inc.
Information provided by (Responsible Party):
Klus Pharma Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Active, not recruiting |
|---|---|
| Actual Primary Completion Date : | March 31, 2022 |
| Estimated Study Completion Date : | December 2022 |